HIC1: A Potential Drug Target and Biomarker (G3090)

Target Name: HIC1

NCBI ID: G3090

HIC1

HIC1: A Potential Drug Target and Biomarker

Hic1, also known as heat shock protein 1, is a protein that is expressed in various tissues and cells throughout the body. It is a key component of the heat shock response, which is a cellular response to increased temperatures, and is involved in the regulation of various cellular processes, including cell survival, metabolism, and stress resistance.

HIC1 has been identified as a potential drug target due to its involvement in a number of diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has also been associated with various biomarkers, making it an attractive target for research into disease diagnosis and treatment.

One of the key advantages of HIC1 as a drug target is its expressedness in a wide range of tissues and cells, including neurons, macrophages, and cancer cells. This makes it an attractive target for drugs that can inhibit its activity throughout the body, rather than just in a specific cell type. Additionally, HIC1 is involved in a number of important cellular processes, which makes it an attractive target for drugs that can modulate its activity and have a more general impact on cellular function.

In cancer, HIC1 has been shown to be involved in a number of important processes, including cell survival, angiogenesis, and immune evasion. For example, studies have shown that HIC1 can promote the growth and survival of cancer cells, and that it is involved in the development of angiases, which are areas of new blood vessels that form in tumors. Additionally, HIC1 has been shown to play a role in immune evasion, as it has been shown to reduce the antigen presentation of cancer cells to T cells.

In neurodegenerative diseases, HIC1 has been associated with a number of cognitive and motor impairments. For example, studies have shown that HIC1 is involved in the regulation of neurotransmitter release from neurons, and that its activity is disrupted in a number of neurodegenerative diseases. Additionally, HIC1 has been shown to be involved in the development of neurofibrillary tangles, which are thought to contribute to the neurofibrillary pathology seen in neurodegenerative diseases.

In autoimmune disorders, HIC1 has been associated with the development of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. Studies have shown that HIC1 is involved in the regulation of immune cell function, and that its activity is disrupted in a number of autoimmune disorders.

Despite the potential benefits of HIC1 as a drug target, there are also potential drawbacks to its use. For example, HIC1 is involved in a number of important cellular processes that are necessary for cell survival, and inhibiting its activity can have a number of potential consequences, including the disruption of cellular homeostasis. Additionally, HIC1 is a protein that is expressed in a wide range of tissues and cells, which can make it difficult to target with drugs.

Overall, HIC1 is an attractive drug target due to its expressedness in a wide range of tissues and cells, and its involvement in a number of important cellular processes that are involved in disease. While there are potential drawbacks to its use, its potential as a drug target makes it an important area of research for the development of new treatments for a wide range of diseases.

Protein Name: HIC ZBTB Transcriptional Repressor 1

Functions: Transcriptional repressor (PubMed:12052894, PubMed:15231840). Recognizes and binds to the consensus sequence '5-[CG]NG[CG]GGGCA[CA]CC-3' (PubMed:15231840). May act as a tumor suppressor (PubMed:20154726). Involved in development of head, face, limbs and ventral body wall (By similarity). Involved in down-regulation of SIRT1 and thereby is involved in regulation of p53/TP53-dependent apoptotic DNA-damage responses (PubMed:16269335). The specific target gene promoter association seems to be depend on corepressors, such as CTBP1 or CTBP2 and MTA1 (PubMed:12052894, PubMed:20547755). In cooperation with MTA1 (indicative for an association with the NuRD complex) represses transcription from CCND1/cyclin-D1 and CDKN1C/p57Kip2 specifically in quiescent cells (PubMed:20547755). Involved in regulation of the Wnt signaling pathway probably by association with TCF7L2 and preventing TCF7L2 and CTNNB1 association with promoters of TCF-responsive genes (PubMed:16724116). Seems to repress transcription from E2F1 and ATOH1 which involves ARID1A, indicative for the participation of a distinct SWI/SNF-type chromatin-remodeling complex (PubMed:18347096, PubMed:19486893). Probably represses transcription of ACKR3, FGFBP1 and EFNA1 (PubMed:16690027, PubMed:19525223, PubMed:20154726)

The "HIC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HIC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets